Rosenberg et al.57, 112used TCR‐T targeting MAGE‐A3 to treat a variety of advanced metastatic solid tumors and achieved positive clinical efficacy; they confirmed the efficacy of MHCII‐TCR CD4 T cell therapy targeting MAGE‐A3 and expanded the therapeutic range of TCR‐T for metastatic tumors. The gene discussed is MAGEA3; the disease is metastatic neoplasm.